With recent Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval of CDK 4/6 inhibitors treatment landscape for post-menopausal women with hormone receptor positive (HR+) and human epidermal growth receptor 2 negative (HER2−) advanced breast cancer is likely to change and is going to bring about new alternatives. The gene discussed is HR; the disease is breast cancer.